Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

42 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-18

Study Completion Date

2022-05-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to summarize kidney histopathological findings in patients with coronavirus disease 2019 (COVID-19) and post-severe acute respiratory syndrome-coronavirus-type 2 (SARS-CoV-2) vaccination.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pathology of Hepatitis c Nephropathy

NCT03476031

Cryoglobulinaemia Due to Chronic Hepatitis C

UNKNOWN

Neutralizing Antibody Level After COVID-19 Vaccination

NCT05083026

Covid19

UNKNOWN

Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms

NCT05484700

Long COVID-19

UNKNOWN

Mucocutaneous Manifestations in Patients With Chronic Kidney Disease inNewVally and Assuit;Hospital Based Study

NCT05819320

Chronic Kidney Diseases Manifestation, Skin

NOT_YET_RECRUITING

COVID-19 IgG Formation in Physicians at ALGH and Their Household Members

NCT04540484

Covid19 SARS-CoV Infection Communicable Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The SARS-CoV-2 pandemic has had substantial global morbidity and mortality. While COVID-19 is most commonly characterized as a respiratory illness, extrapulmonary manifestations are a prominent part its clinical spectrum. Kidney disease is a common finding in COVID-19, and has also been rarely described after SARS-CoV-2 vaccination. The main objective of this study is to summarize kidney histopathological findings in patients with COVID-19 and post-SARS-COV-2 vaccination, in whom native kidney biopsy was performed and samples were obtained by the Nephropathology Section, Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Vaccination Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with COVID-19

Polymerase Chain Reaction-positive SARS-CoV-2 infection

No interventions assigned to this group

Patients post-SARS-CoV-2 vaccination

Onset of kidney disease potentially relatable to SARS-CoV-2 vaccination based on clinical grounds

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* being diagnosed with COVID-19 when kidney biopsy was performed
* history of recent homologous or heterogenous vaccine regimen comprising either vector-based vaccines or messenger ribonucleic acid-based vaccines